Goldman Sachs Group Inc. Boosts Stake in Verrica Pharmaceuticals Inc. $VRCA

Goldman Sachs Group Inc. grew its stake in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 23.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 139,055 shares of the company’s stock after buying an additional 26,308 shares during the quarter. Goldman Sachs Group Inc. owned 0.15% of Verrica Pharmaceuticals worth $61,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Bank of America Corp DE raised its position in Verrica Pharmaceuticals by 347.5% in the 4th quarter. Bank of America Corp DE now owns 143,818 shares of the company’s stock worth $101,000 after purchasing an additional 111,678 shares during the period. Kovitz Investment Group Partners LLC purchased a new position in Verrica Pharmaceuticals in the 1st quarter worth $45,000. Charles Schwab Investment Management Inc. raised its position in Verrica Pharmaceuticals by 127.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company’s stock worth $44,000 after purchasing an additional 55,852 shares during the period. AQR Capital Management LLC raised its position in Verrica Pharmaceuticals by 306.7% in the 1st quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock worth $26,000 after purchasing an additional 44,275 shares during the period. Finally, Invesco Ltd. raised its position in Verrica Pharmaceuticals by 64.8% in the 1st quarter. Invesco Ltd. now owns 74,388 shares of the company’s stock worth $33,000 after purchasing an additional 29,256 shares during the period. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ:VRCA opened at $4.31 on Wednesday. The stock has a market cap of $40.73 million, a PE ratio of -0.52 and a beta of 1.78. The company’s fifty day moving average is $5.48 and its 200 day moving average is $5.68. Verrica Pharmaceuticals Inc. has a 52 week low of $3.82 and a 52 week high of $17.38.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings results on Tuesday, August 12th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.72. The firm had revenue of $12.70 million during the quarter, compared to the consensus estimate of $4.37 million. Sell-side analysts anticipate that Verrica Pharmaceuticals Inc. will post -1.46 EPS for the current year.

Verrica Pharmaceuticals Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.